RU2003100517A - Новый интерферон для лечения рассеянного склероза - Google Patents
Новый интерферон для лечения рассеянного склероза Download PDFInfo
- Publication number
- RU2003100517A RU2003100517A RU2003100517/15A RU2003100517A RU2003100517A RU 2003100517 A RU2003100517 A RU 2003100517A RU 2003100517/15 A RU2003100517/15 A RU 2003100517/15A RU 2003100517 A RU2003100517 A RU 2003100517A RU 2003100517 A RU2003100517 A RU 2003100517A
- Authority
- RU
- Russia
- Prior art keywords
- biologically active
- multiple sclerosis
- pharmaceutical composition
- mammals
- mammal
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title claims 5
- 102000014150 Interferons Human genes 0.000 title 1
- 108010050904 Interferons Proteins 0.000 title 1
- 229940079322 interferon Drugs 0.000 title 1
- 241000124008 Mammalia Species 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (6)
1. Фармацевтическая композиция, предназначенная для лечения рассеянного склероза у млекопитающих, содержащая фармацевтически приемлемый эксципиент и терапевтически эффективное количество полипептида человеческого IFN-β2, представленного на фиг.2, его биологически активного фрагмента или его биологически активного производного.
2. Фармацевтическая композиция по п.1, где млекопитающее, нуждающееся во введении такой композиции, представляет собой человека.
3. Способ введения млекопитающему, нуждающемуся в таком введении, фармацевтической композиции, предназначенной для лечения рассеянного склероза у млекопитающих, которая содержит фармацевтически приемлемый эксципиент и терапевтически эффективное количество полипептида человеческого IFN-β2, представленного на фиг.2, его биологически активного фрагмента или его биологически активного производного.
4. Способ по п.3, где млекопитающее, нуждающееся в таком введении, представляет собой человека.
5. Фармацевтическая композиция, предназначенная для лечения рассеянного склероза у млекопитающих, содержащая фармацевтически приемлемый эксципиент и терапевтически эффективное количество полипептида человеческого IFN-β2, его биологически активного фрагмента или его биологически активного производного.
6. Способ введения млекопитающему, нуждающемуся в таком введении, фармацевтической композиции, предназначенной для лечения рассеянного склероза у млекопитающих, которая содержит фармацевтически приемлемый эксципиент и терапевтически эффективное количество полипептида человеческого IFN-β2, его биологически активного фрагмента или его биологически активного производного.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21204600P | 2000-06-16 | 2000-06-16 | |
| US60/212,046 | 2000-06-16 | ||
| US09/881,050 | 2001-06-15 | ||
| US09/881,050 US20020025304A1 (en) | 2000-06-16 | 2001-06-15 | Novel interferon for the treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2003100517A true RU2003100517A (ru) | 2004-06-27 |
Family
ID=26906704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003100517/15A RU2003100517A (ru) | 2000-06-16 | 2001-06-18 | Новый интерферон для лечения рассеянного склероза |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20020025304A1 (ru) |
| EP (1) | EP1289541A2 (ru) |
| JP (1) | JP2004505021A (ru) |
| KR (1) | KR20030009529A (ru) |
| CN (1) | CN1436086A (ru) |
| AU (1) | AU2001267099A1 (ru) |
| BG (1) | BG107370A (ru) |
| BR (1) | BR0111852A (ru) |
| CA (1) | CA2413077A1 (ru) |
| CZ (1) | CZ20024094A3 (ru) |
| EE (1) | EE200200693A (ru) |
| HU (1) | HUP0300787A2 (ru) |
| IL (1) | IL152996A0 (ru) |
| LT (1) | LT2002123A (ru) |
| MX (1) | MXPA02012308A (ru) |
| NO (1) | NO20025964L (ru) |
| NZ (1) | NZ522849A (ru) |
| PL (1) | PL359562A1 (ru) |
| RU (1) | RU2003100517A (ru) |
| SI (1) | SI21080A (ru) |
| SK (1) | SK17612002A3 (ru) |
| WO (1) | WO2001095929A2 (ru) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ540043A (en) * | 2002-11-18 | 2007-11-30 | Maxygen Inc | Isolated or recombinant Interferon-alpha polypeptides and conjugates |
| US7314613B2 (en) * | 2002-11-18 | 2008-01-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
| EP1712992A1 (en) * | 2005-04-11 | 2006-10-18 | Sony Ericsson Mobile Communications AB | Updating of data instructions |
| WO2011103164A1 (en) * | 2010-02-18 | 2011-08-25 | Centocor Ortho Biotech Inc. | Monkey homolog of human interferon omega |
| DK3411398T3 (da) | 2016-02-05 | 2024-06-24 | Orionis Biosciences BV | Målrettede terapeutiske midler og anvendelse heraf |
| US11384154B2 (en) | 2017-02-06 | 2022-07-12 | Orionis Biosciences BV | Targeted chimeric proteins and uses thereof |
| JP7586579B2 (ja) | 2017-02-06 | 2024-11-19 | オリオンズ バイオサイエンス インコーポレイテッド | 標的化改変型インターフェロン及びその使用 |
| US20200354424A1 (en) | 2018-01-26 | 2020-11-12 | Orionis Biosciences, Inc. | Xcr1 binding agents and uses thereof |
| WO2024192373A1 (en) * | 2023-03-16 | 2024-09-19 | A-Alpha Bio | Interferon alpha-2 variants |
| US12281147B2 (en) | 2023-08-14 | 2025-04-22 | A-Alpha Bio, Inc. | Interleukin 21 variants |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6372206B1 (en) * | 1989-03-02 | 2002-04-16 | University Of Florida | Orally-administered interferon-TAU compositions and methods |
| EP0758902A1 (en) * | 1994-05-10 | 1997-02-26 | Immulogic Pharmaceutical Corporation | Compositions and treatment for multiple sclerosis |
| IL136326A0 (en) * | 1997-12-08 | 2001-05-20 | Genentech Inc | Human interferon-epsilon: a type i interferon |
| EA200001252A1 (ru) * | 1998-05-29 | 2001-06-25 | Байоджен, Инк. | КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА-β-1A(IFN-β-1A) ЧЕЛОВЕКА |
| IL142061A0 (en) * | 1998-09-18 | 2002-03-10 | Zymogenetics Inc | Interferon-epsilon |
| US20030175897A1 (en) * | 2000-04-14 | 2003-09-18 | Thayer Edward C. | Human interferon, Zinf2 |
-
2001
- 2001-06-15 US US09/881,050 patent/US20020025304A1/en not_active Abandoned
- 2001-06-18 IL IL15299601A patent/IL152996A0/xx unknown
- 2001-06-18 CZ CZ20024094A patent/CZ20024094A3/cs unknown
- 2001-06-18 HU HU0300787A patent/HUP0300787A2/hu unknown
- 2001-06-18 EE EEP200200693A patent/EE200200693A/xx unknown
- 2001-06-18 SI SI200120032A patent/SI21080A/sl not_active IP Right Cessation
- 2001-06-18 EP EP01944716A patent/EP1289541A2/en not_active Withdrawn
- 2001-06-18 SK SK1761-2002A patent/SK17612002A3/sk unknown
- 2001-06-18 AU AU2001267099A patent/AU2001267099A1/en not_active Abandoned
- 2001-06-18 CN CN01811184A patent/CN1436086A/zh active Pending
- 2001-06-18 PL PL01359562A patent/PL359562A1/xx not_active Application Discontinuation
- 2001-06-18 WO PCT/US2001/041022 patent/WO2001095929A2/en not_active Application Discontinuation
- 2001-06-18 BR BR0111852-8A patent/BR0111852A/pt not_active Application Discontinuation
- 2001-06-18 NZ NZ522849A patent/NZ522849A/en unknown
- 2001-06-18 MX MXPA02012308A patent/MXPA02012308A/es unknown
- 2001-06-18 CA CA002413077A patent/CA2413077A1/en not_active Abandoned
- 2001-06-18 RU RU2003100517/15A patent/RU2003100517A/ru not_active Application Discontinuation
- 2001-06-18 JP JP2002510107A patent/JP2004505021A/ja active Pending
- 2001-06-18 KR KR1020027017090A patent/KR20030009529A/ko not_active Withdrawn
-
2002
- 2002-12-02 LT LT2002123A patent/LT2002123A/xx unknown
- 2002-12-11 BG BG107370A patent/BG107370A/xx unknown
- 2002-12-12 NO NO20025964A patent/NO20025964L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001267099A1 (en) | 2001-12-24 |
| WO2001095929A2 (en) | 2001-12-20 |
| PL359562A1 (en) | 2004-08-23 |
| NO20025964L (no) | 2003-02-14 |
| KR20030009529A (ko) | 2003-01-29 |
| LT2002123A (en) | 2003-06-25 |
| CN1436086A (zh) | 2003-08-13 |
| WO2001095929A3 (en) | 2002-10-10 |
| SI21080A (sl) | 2003-06-30 |
| EE200200693A (et) | 2004-06-15 |
| MXPA02012308A (es) | 2003-04-25 |
| JP2004505021A (ja) | 2004-02-19 |
| EP1289541A2 (en) | 2003-03-12 |
| IL152996A0 (en) | 2003-06-24 |
| BR0111852A (pt) | 2003-05-20 |
| BG107370A (en) | 2003-11-28 |
| NZ522849A (en) | 2004-05-28 |
| HUP0300787A2 (hu) | 2003-07-28 |
| US20020025304A1 (en) | 2002-02-28 |
| SK17612002A3 (sk) | 2003-08-05 |
| NO20025964D0 (no) | 2002-12-12 |
| CZ20024094A3 (cs) | 2003-05-14 |
| CA2413077A1 (en) | 2001-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118849T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
| DE69914463D1 (en) | Therapeutische chemokine rezeptor antagonisten | |
| KR950002785A (ko) | 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜 | |
| KR930702022A (ko) | 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법 | |
| DE69129248D1 (de) | Peptide mit Endothelin antagonistischer Aktivität, deren Herstellung und pharmazeutische Zusammensetzungen | |
| HUT60630A (en) | Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature | |
| ATE306931T1 (de) | Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer | |
| RU95113492A (ru) | Терапевтическая комбинация, содержащая человеческий интерферон, его применение, фармацевтический препарат, упаковка и способ лечения | |
| ATE329608T1 (de) | Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung | |
| SE9800550D0 (sv) | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof | |
| RU2003100517A (ru) | Новый интерферон для лечения рассеянного склероза | |
| ATE293451T1 (de) | Behandlung der osteoarthritis durch verabreichung von poly-n-acetyl-d-glucosamin | |
| EA199800717A1 (ru) | Способ лечения заболеваний млекопитающих и цвиттерионная композиция | |
| ES2026304A6 (es) | Procedimiento de fabricacion de una forma de dosificacion de nicardipina. | |
| DK0817646T3 (da) | Fremgangsmåder til behandling af inflammation og præparater derfor | |
| CA2501738A1 (en) | Method of treating chronic pelvic pain syndrome by administration of chrorionic gonadotropin | |
| JP2002530353A5 (ru) | ||
| RU97120700A (ru) | Новое фармакологическое применение антагонистов a-ii рецептора | |
| WO1990004977A3 (en) | Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon | |
| RU2001118219A (ru) | Ингибитор ангиогенеза | |
| DE69729201D1 (de) | Sulfonfluoride zur behandlung von der alzheimerischen krankheit | |
| NO993921D0 (no) | Medikament mot infertilitet og for ökt fertilitet | |
| JP2002529515A5 (ru) | ||
| EA200300430A1 (ru) | Новые фармацевтические композиции, содержащие эпинастин и псевдоэфедрин | |
| SE8804640L (sv) | Laekemedel omfattande cyklolinopeptide a |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20050111 |